A Phase Ib/II, Open-label, Multicenter Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies

Trial Profile

A Phase Ib/II, Open-label, Multicenter Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Ricolinostat (Primary)
  • Indications Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 May 2017 Planned number of patients changed from 80 to 40.
    • 16 May 2017 Planned End Date changed from 10 Mar 2017 to 10 Dec 2019.
    • 16 May 2017 Planned primary completion date changed from 25 Feb 2017 to 25 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top